Literature DB >> 28825136

Breast cancer subtype discrimination using standardized 4-IHC and digital image analysis.

Marina Gándara-Cortes1,2, Ángel Vázquez-Boquete3, Beatriz Fernández-Rodríguez4, Patricia Viaño4, Dora Ínsua4, Alejandro Seoane-Seoane4, Francisco Gude5, Rosalía Gallego1, Máximo Fraga4, José R Antúnez4, Teresa Curiel6, Eva Pérez-López7, Tomás García-Caballero1,4.   

Abstract

Breast cancer is a heterogeneous disease. Surrogate classification of intrinsic subtypes of invasive carcinomas by combined immunohistochemistry for estrogen receptor (ER), progesterone receptor (PR), HER2, and Ki67 (4-IHC) has increased steadily since the 2011 St Gallen symposium, due to its rapid subtyping of tumors at a reasonable cost. An important step in improving 4-IHC reproducibility and reliability will be to provide reference values from the routine use of standardized 4-IHC followed by image analysis. The aims of the current study were (1) to analyze invasive breast carcinomas using standardized 4-IHC and quantitative image analysis and (2) to compare the results obtained in the classification of biological subtypes using current Ki67 and PR threshold values proposed by different authors to sub-classifying the luminal A-like and the luminal B-like (HER2-negative) subtypes. Five hundred twenty-one tumors were analyzed by standardized immunohistochemistry, with automatic image analysis, and HER2 FISH technique. Positivity for ER was found in 82.7% and for PR in 70.1% of cases. Using the Allred scoring system, hormone receptor results showed a bimodal distribution, particularly for ER. HER2 positivity was found in 15.7% of cases, and the mean Ki67 score was 32.3%. Using the most recently proposed surrogate definitions for the classification of luminal breast cancer subtypes, the percentages of different subtypes that we found were similar to those published with genomic platforms: 40.7% luminal A-like, 32.4% luminal B-like/HER2-negative, 9.8% luminal B-like/HER2-positive, 6.0% HER2-positive, and 11.1% triple negative. Standardized 4-IHC with automatic image analysis constitutes a low-cost method for surrogate definitions of biological subtypes of breast cancer that delivers accurate results in a day.

Entities:  

Keywords:  4-IHC; Biological subtypes; Breast cancer; Image analysis

Mesh:

Substances:

Year:  2017        PMID: 28825136     DOI: 10.1007/s00428-017-2194-z

Source DB:  PubMed          Journal:  Virchows Arch        ISSN: 0945-6317            Impact factor:   4.064


  41 in total

1.  Prognostic significance of progesterone receptor-positive tumor cells within immunohistochemically defined luminal A breast cancer.

Authors:  Aleix Prat; Maggie Chon U Cheang; Miguel Martín; Joel S Parker; Eva Carrasco; Rosalía Caballero; Scott Tyldesley; Karen Gelmon; Philip S Bernard; Torsten O Nielsen; Charles M Perou
Journal:  J Clin Oncol       Date:  2012-12-10       Impact factor: 44.544

2.  Estrogen receptor negative and progesterone receptor positive breast carcinomas-how frequent are they?

Authors:  Gábor Cserni; Monika Francz; Endre Kálmán; Gyöngyi Kelemen; Detre Csaba Komjáthy; Ilona Kovács; Janina Kulka; László Sarkadi; Nóra Udvarhelyi; László Vass; András Vörös
Journal:  Pathol Oncol Res       Date:  2011-01-26       Impact factor: 3.201

3.  Hormone receptor status and survival in a population-based cohort of patients with breast carcinoma.

Authors:  Victor R Grann; Andrea B Troxel; Naseem J Zojwalla; Judith S Jacobson; Dawn Hershman; Alfred I Neugut
Journal:  Cancer       Date:  2005-06-01       Impact factor: 6.860

4.  Breast cancer classification according to immunohistochemical markers: clinicopathologic features and short-term survival analysis in a population-based study from the South of Switzerland.

Authors:  A Spitale; P Mazzola; D Soldini; L Mazzucchelli; A Bordoni
Journal:  Ann Oncol       Date:  2008-12-12       Impact factor: 32.976

5.  Clinical outcome and global gene expression data support the existence of the estrogen receptor-negative/progesterone receptor-positive invasive breast cancer phenotype.

Authors:  Werner Schroth; S Winter; F Büttner; S Goletz; S Faißt; F Brinkmann; P Saladores; E Heidemann; G Ott; A Gerteis; M D Alscher; J Dippon; M Schwab; H Brauch; P Fritz
Journal:  Breast Cancer Res Treat       Date:  2015-12-09       Impact factor: 4.872

Review 6.  Breast carcinoma: is molecular evaluation a necessary part of current pathological analysis?

Authors:  Rima Koka; Olga B Ioffe
Journal:  Semin Diagn Pathol       Date:  2013-11-12       Impact factor: 3.464

7.  Quality assessment of estrogen receptor and progesterone receptor testing in breast cancer using a tissue microarray-based approach.

Authors:  T J A Dekker; S ter Borg; G K J Hooijer; S L Meijer; J Wesseling; J E Boers; E Schuuring; J Bart; J van Gorp; P Bult; S A Riemersma; C H M van Deurzen; H F B M Sleddens; W E Mesker; J R Kroep; V T H B M Smit; M J van de Vijver
Journal:  Breast Cancer Res Treat       Date:  2015-06-04       Impact factor: 4.872

8.  Proposed new clinicopathological surrogate definitions of luminal A and luminal B (HER2-negative) intrinsic breast cancer subtypes.

Authors:  Patrick Maisonneuve; Davide Disalvatore; Nicole Rotmensz; Giuseppe Curigliano; Marco Colleoni; Silvia Dellapasqua; Giancarlo Pruneri; Mauro G Mastropasqua; Alberto Luini; Fabio Bassi; Gianmatteo Pagani; Giuseppe Viale; Aron Goldhirsch
Journal:  Breast Cancer Res       Date:  2014-06-20       Impact factor: 6.466

9.  Prognostic value of automated KI67 scoring in breast cancer: a centralised evaluation of 8088 patients from 10 study groups.

Authors:  Mustapha Abubakar; Nick Orr; Frances Daley; Penny Coulson; H Raza Ali; Fiona Blows; Javier Benitez; Roger Milne; Herman Brenner; Christa Stegmaier; Arto Mannermaa; Jenny Chang-Claude; Anja Rudolph; Peter Sinn; Fergus J Couch; Peter Devilee; Rob A E M Tollenaar; Caroline Seynaeve; Jonine Figueroa; Mark E Sherman; Jolanta Lissowska; Stephen Hewitt; Diana Eccles; Maartje J Hooning; Antoinette Hollestelle; John W M Martens; Carolien H M van Deurzen; Manjeet K Bolla; Qin Wang; Michael Jones; Minouk Schoemaker; Jelle Wesseling; Flora E van Leeuwen; Laura Van 't Veer; Douglas Easton; Anthony J Swerdlow; Mitch Dowsett; Paul D Pharoah; Marjanka K Schmidt; Montserrat Garcia-Closas
Journal:  Breast Cancer Res       Date:  2016-10-18       Impact factor: 6.466

10.  Ki-67 is a prognostic parameter in breast cancer patients: results of a large population-based cohort of a cancer registry.

Authors:  E C Inwald; M Klinkhammer-Schalke; F Hofstädter; F Zeman; M Koller; M Gerstenhauer; O Ortmann
Journal:  Breast Cancer Res Treat       Date:  2013-05-16       Impact factor: 4.872

View more
  4 in total

1.  Analysis of membranous Ki-67 staining in breast cancer and surrounding breast epithelium.

Authors:  Gábor Cserni
Journal:  Virchows Arch       Date:  2018-03-28       Impact factor: 4.064

2.  Evaluating the Prediction of Breast Cancer Survival Using Lymph Node Ratio.

Authors:  Man Hung; Julie Xu; Dominique Nielson; Jerry Bounsanga; Yushan Gu; Alec Roger Hansen; Maren Wright Voss
Journal:  J Breast Cancer       Date:  2018-08-28       Impact factor: 3.588

3.  Factors influencing agreement of breast cancer luminal molecular subtype by Ki67 labeling index between core needle biopsy and surgical resection specimens.

Authors:  Kristina A Tendl-Schulz; Fabian Rössler; Philipp Wimmer; Ulrike M Heber; Martina Mittlböck; Nicolas Kozakowski; Katja Pinker; Rupert Bartsch; Peter Dubsky; Florian Fitzal; Martin Filipits; Fanny Carolina Eckel; Eva-Maria Langthaler; Günther Steger; Michael Gnant; Christian F Singer; Thomas H Helbich; Zsuzsanna Bago-Horvath
Journal:  Virchows Arch       Date:  2020-05-07       Impact factor: 4.064

4.  Correlation of ER, PR, and HER2 at the protein and mRNA levels in Asian patients with operable breast cancer.

Authors:  Chih-Jung Chen; Ting-Hao Chen; Jason Lei; Ji-An Liang; Po-Sheng Yang; Chiun-Sheng Huang; Chia-Ming Hsieh; Ling-Ming Tseng; Liang-Chih Liu; Skye Hung-Chen Cheng; Kuan-Hui Shih
Journal:  Biosci Rep       Date:  2022-01-28       Impact factor: 3.840

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.